EirGenix
Biosimilar developer, Taiwan. 1 development product across 1 molecule: trastuzumab.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Trastuzumab | Herwenda EG12014 | · | Nov 2023 | · | · | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
In development
ClinicalTrials.gov lists one comparative trial sponsored by EirGenix for one molecule: pertuzumab. Candidates without an approval yet in the seven markets: EG1206A.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Pertuzumab | EG1206A | EirGenix | Perjeta | Phase 1 | Comparative PK | Completed | May 2022 | Jan 2023 | no approval in the seven markets | NCT05471648 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with EirGenix, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- EMANov 2023Herwenda, trastuzumab
Compare EirGenix with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant